Kenneth C Bagley
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$11.2MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $11.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 31, 2026 | NIH | SBIR Phase II Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens | $1.0M | ORLANCE, INC |
| Aug 8, 2024 | NIH | SBIR Phase II Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens | $300K | ORLANCE, INC |
| Apr 30, 2024 | NIH | SBIR Phase II Universal Influenza A/B Vaccine | $1.0M | ORLANCE, INC |
| Sep 21, 2023 | NIH | SBIR Phase I Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma. | $200K | ORLANCE, INC |
| Aug 21, 2023 | NIH | SBIR Phase II Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine | $997K | ORLANCE, INC |
| May 23, 2023 | NIH | SBIR Phase II Universal Influenza A/B Vaccine | $999K | ORLANCE, INC |
| May 3, 2022 | NIH | SBIR Phase II Universal Influenza A/B Vaccine | $1.0M | ORLANCE, INC |
| May 6, 2021 | NIH | SBIR Phase II Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | $955K | ORLANCE, INC |
| Apr 30, 2021 | NIH | SBIR Phase II DNA prime / rVSV boost Multi-Antigen Universal Influenza Vaccine | $1.0M | ORLANCE, INC |
| Aug 7, 2020 | NIH | SBIR Phase II Universal Influenza A/B Vaccine | $300K | ORLANCE, INC |
| Jun 2, 2020 | NIH | SBIR Phase II Development of a rapid response nucleic acid vaccine strategy for coronavirusepidemics | $909K | ORLANCE, INC |
| Apr 9, 2020 | NIH | SBIR Phase II DNA prime / rVSV boost Multi-Antigen Universal Influenza Vaccine | $1.0M | ORLANCE, INC |
| Aug 23, 2019 | NIH | SBIR Phase II Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine | $570K | ORLANCE, INC |
| Aug 16, 2019 | NIH | SBIR Phase II DNA prime / rVSV boost Multi-Antigen Universal Influenza Vaccine | $1.0M | ORLANCE, INC |
Peer ranks
Federal funding#60
Awards as PI#65
Patents#505
Companies
- ORLANCE, INCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.